Sulfur-Based Supplement May Fight Arthritis
Posted on: Tuesday, 30 August 2005, 18:01 CDT
TUESDAY, Aug. 30 (HealthDay News) -- A naturally occurring sulfur compound decreased pain and improved physical function in patients with knee arthritis, researchers report.
Methylsulfonylmethane, or MSM, has become a popular dietary supplement, but few studies have been conducted involving patients.
Researchers administered 3 grams of MSM twice a day to 25 arthritis sufferers in a randomized, double-blind trial for 12 weeks. The team consisted of doctors from the Southwest College of Naturopathic Medicine in Tempe, Ariz., and the Arthritis Health Center in Scottsdale, Ariz.
The patients taking MSM reported significant decreases in pain and improvements in their physical function, compared with a control group taking a placebo, the researchers said.
However, no notable differences were found in stiffness or aggregated total symptoms.
The findings were presented last week at the annual meeting of the American Association of Naturopathic Physicians in Phoenix.
More information
The Arthritis Foundation has more about MSM.
SOURCES: American Association of Naturopathic Physicians, news release, Aug. 24, 2005~PAIN~~KNEE~~ARTH~~ALTM~
Source: HealthSCOUT
Related Articles
- Plasma Protein Therapeutics Association Supports Patient-Centered Outcomes Research Act of 2009
- NIH Stem Cell Guidelines Ethically Irresponsible, Scientifically Unworthy, Useless to Patients, Says Family Research Council
- Research Tests Reliability of More Accurate Measure of Patient Pain
- ACTEMRA (R) (Tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments
- Treat Your Patients' Pain Effectively
- Odense University Hospital Revolutionizes Patient Care and Research With Hyland Software's OnBase Solution
- Mammograms for Women in Their 40s Should Be Based on Individual Cancer Risks, Patient Preferences, Stanford Researcher Says
- The Leukemia & Lymphoma Society Unveils New Education Series for Myeloma Patients Covering Latest Research and Treatment Options
- Merck Partners Neuromed for Pain Drug Research
- Organ Tolerance for Transplant Patients Focus of Research Presented at ISHLT
 |
 |
User Comments (0)
RSS Feeds